Regeneron Pharmaceuticals' Phase 3 Trial of Garetosmab in Fibrodysplasia Ossificans Progressiva Meets Primary Endpoint

MT Newswires Live

Sep 17

Regeneron Pharmaceuticals (REGN) said Wednesday its phase 3 study of garetosmab in adults with fibrodysplasia ossificans progressiva, or FOP, met its primary endpoint, demonstrating a greater reduction in new bone lesions compared with placebo.

The company said the trial enrolled 63 people with FOP aged at least 18 years old. The primary and key secondary endpoints were assessed at 56 weeks, with results indicating a reduction in total new lesion volume with garetosmab, Regeneron added.

Regeneron said it plans to complete the US regulatory submission for garetosmab in FOP by year-end, to be followed by global regulatory submissions in 2026. The company said it also expects to start a phase 3 trial of garetosmab in adolescents and children with FOP in 2026.

Regeneron shares were fractionally higher in premarket trading.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2568493493"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568493493\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568493493?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-17 19:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568493493","market":"sh","top_or_hot":-1,"title":"Regeneron Pharmaceuticals' Phase 3 Trial of Garetosmab in Fibrodysplasia Ossificans Progressiva Meets Primary Endpoint","media":"MT Newswires Live","content":"<html><body><p> Regeneron Pharmaceuticals (REGN) said Wednesday its phase 3 study of garetosmab in adults with fibrodysplasia ossificans progressiva, or FOP, met its primary endpoint, demonstrating a greater reduction in new bone lesions compared with placebo.</p><p>The company said the trial enrolled 63 people with FOP aged at least 18 years old. The primary and key secondary endpoints were assessed at 56 weeks, with results indicating a reduction in total new lesion volume with garetosmab, Regeneron added.</p><p>Regeneron said it plans to complete the US regulatory submission for garetosmab in FOP by year-end, to be followed by global regulatory submissions in 2026. The company said it also expects to start a phase 3 trial of garetosmab in adolescents and children with FOP in 2026.</p><p>Regeneron shares were fractionally higher in premarket trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Regeneron Pharmaceuticals' Phase 3 Trial of Garetosmab in Fibrodysplasia Ossificans Progressiva Meets Primary Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRegeneron Pharmaceuticals' Phase 3 Trial of Garetosmab in Fibrodysplasia Ossificans Progressiva Meets Primary Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-17 19:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Regeneron Pharmaceuticals (REGN) said Wednesday its phase 3 study of garetosmab in adults with fibrodysplasia ossificans progressiva, or FOP, met its primary endpoint, demonstrating a greater reduction in new bone lesions compared with placebo.</p><p>The company said the trial enrolled 63 people with FOP aged at least 18 years old. The primary and key secondary endpoints were assessed at 56 weeks, with results indicating a reduction in total new lesion volume with garetosmab, Regeneron added.</p><p>Regeneron said it plans to complete the US regulatory submission for garetosmab in FOP by year-end, to be followed by global regulatory submissions in 2026. The company said it also expects to start a phase 3 trial of garetosmab in adolescents and children with FOP in 2026.</p><p>Regeneron shares were fractionally higher in premarket trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"REGN","symbol_name":"再生元制药公司","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568493493","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568493493","pubTimestamp":1758109693,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Regeneron Pharmaceuticals  said Wednesday its phase 3 study of garetosmab in adults with fibrodysplasia ossificans progressiva, or FOP, met its primary endpoint, demonstrating a greater reduction in new bone lesions compared with placebo.The company said the trial enrolled 63 people with FOP aged at least 18 years old. The primary and key secondary endpoints were assessed at 56 weeks, with results indicating a reduction in total new lesion volume with garetosmab, Regeneron added.Regeneron said it plans to complete the US regulatory submission for garetosmab in FOP by year-end, to be followed by global regulatory submissions in 2026. The company said it also expects to start a phase 3 trial of garetosmab in adolescents and children with FOP in 2026.Regeneron shares were fractionally higher in premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"REGN":"再生元制药公司","LU2362541273.HKD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (HKD) ACC","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","BK4588":"碎股","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU0882574055.USD":"富达全球健康医疗A ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU1974910355.USD":"Allianz Thematica Cl AMg DIS USD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0823434583.USD":"BNP PARIBAS US GROWTH \"C\" (USD) ACC","LU0058720904.USD":"联博国际健康护理基金A","LU2237438978.USD":"Amundi Funds US Pioneer A2 (C) USD","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU0053666078.USD":"摩根大通基金-美国股票A（离岸）美元"},"translate_title":"再生元制药Garetosmab治疗进行性骨化性纤维发育不良的3期试验达到主要终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"REGN":1.5},"content_text":"Regeneron Pharmaceuticals (REGN) said Wednesday its phase 3 study of garetosmab in adults with fibrodysplasia ossificans progressiva, or FOP, met its primary endpoint, demonstrating a greater reduction in new bone lesions compared with placebo.The company said the trial enrolled 63 people with FOP aged at least 18 years old. The primary and key secondary endpoints were assessed at 56 weeks, with results indicating a reduction in total new lesion volume with garetosmab, Regeneron added.Regeneron said it plans to complete the US regulatory submission for garetosmab in FOP by year-end, to be followed by global regulatory submissions in 2026. The company said it also expects to start a phase 3 trial of garetosmab in adolescents and children with FOP in 2026.Regeneron shares were fractionally higher in premarket trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}